To evaluate the potential of NfL levels as a biomarker in genetic FTD, we determined CSF and serum NfL in presymptomatic carriers and patients with pathogenic mutations in MAPT, GRN or C9orf72, and correlated these levels with clinical and neuroimaging measures. This evidence concerns the gene NEFL and frontotemporal dementia.